Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
about
Nanoformulations of Rilpivirine for Topical Pericoital and Systemic Coitus-Independent Administration Efficiently Prevent HIV TransmissionThe potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trialsA review of nanotechnological approaches for the prophylaxis of HIV/AIDS.Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.Nanoparticle-based drug delivery to the vagina: a review.Development and validation of a simple and isocratic reversed-phase HPLC method for the determination of rilpivirine from tablets, nanoparticles and HeLa cell lysates.Topical Tenofovir Disoproxil Fumarate Nanoparticles Prevent HIV-1 Vaginal Transmission in a Humanized Mouse ModelNovel intravaginal nanomedicine for the targeted delivery of saquinavir to CD4+ immune cells.Vaginal drug delivery: strategies and concerns in polymeric nanoparticle development.Smart nanoparticles as targeting platforms for HIV infections.Design and in vitro evaluation of tenofovir-loaded vaginal gels for the prevention of HIV infections.Thermosensitive Gel Containing Cellulose Acetate Phthalate-Efavirenz Combination Nanoparticles for Prevention of HIV-1 Infection.Antiretroviral solid drug nanoparticles with enhanced oral bioavailability: production, characterization, and in vitro-in vivo correlation.Efaverinz and nano-gold-loaded mannosylated niosomes: a host cell-targeted topical HIV-1 prophylaxis via thermogel system.Proniosomes derived niosomes: recent advancements in drug delivery and targeting.Thermosensitive hydrogels a versatile concept adapted to vaginal drug delivery.Development of peptide inhibitors of HIV transmission.Nanoparticle Encapsulation for Antiretroviral Pre-Exposure Prophylaxis.
P2860
Q27318354-AFBBFEF2-ABB9-4F19-A46D-38BC80CA9715Q28087336-C481A93F-C3F5-4816-9779-24B1956CC811Q30431343-7A7EA4DE-9B5F-4DA3-81DE-B86D55CECF6BQ33821090-A45E4680-A487-443B-A6E2-FA59981AE13BQ34079533-B45BAB71-0E6A-4E48-B310-4D1068ADA70AQ35314702-50FD8B00-C8F7-4907-9B2A-84081DD30B72Q36933427-CEA52A51-58BE-4904-A89E-28B334FD7B91Q37095750-F8E37349-FBE8-4B4D-B5AA-10EFFDD1C93EQ38222809-769F35DB-6352-45A5-8294-09A34B8EA640Q38887077-416FDDE7-B352-4866-AD12-5B92D5B76B0AQ40201612-23B1CFA5-A675-465A-813A-416F579E2518Q41033215-DC65B47E-9B47-4264-B0DA-EE04EDB234BCQ46448056-8327A255-80CA-47C5-8514-F4E97DC20345Q47259034-A127EC99-A27D-49B0-A93E-4073B2A3C3B0Q47355869-0A387C7A-3D3F-4B6B-8DF8-957B6BB5921AQ47591959-43BB75EB-6D4C-48CF-A88F-46882019A709Q55317261-9DC840ED-713F-4462-BBB6-396AD399C203Q55338133-86B653A1-7C08-4485-882E-AE8959332629
P2860
Development and evaluation of a thermosensitive vaginal gel containing raltegravir+efavirenz loaded nanoparticles for HIV prophylaxis.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Development and evaluation of ...... particles for HIV prophylaxis.
@ast
Development and evaluation of ...... particles for HIV prophylaxis.
@en
type
label
Development and evaluation of ...... particles for HIV prophylaxis.
@ast
Development and evaluation of ...... particles for HIV prophylaxis.
@en
prefLabel
Development and evaluation of ...... particles for HIV prophylaxis.
@ast
Development and evaluation of ...... particles for HIV prophylaxis.
@en
P2093
P2860
P1433
P1476
Development and evaluation of ...... particles for HIV prophylaxis.
@en
P2093
Annemarie Shibata
Bridget Sanford
Krista La Bruzzo
Michael Goede
Michel Belshan
P2860
P304
P356
10.1016/J.ANTIVIRAL.2012.09.015
P577
2012-10-03T00:00:00Z